Remove Manufacturing Remove Patients Remove Side effects
article thumbnail

“Game-changing” obesity drug over-promising?

World of DTC Marketing

Patients want quick fixes, and the idea of losing some weight because of a new drug is enticing to them. In response, the company has been providing six-month waivers to some insured patients that will cap the drug’s out-of-pocket costs at $25 a month, though the long-term picture of coverage is still in flux. Click to Tweet.

Insurance 271
article thumbnail

OSD contract manufacturing market valued at $54.7 billion by 2030

European Pharmaceutical Review

A market report has projected that the global oral solid dosage (OSD) contract manufacturing market is expected to be worth $54.7 Data showed that worldwide, oral solids are the most popular mode of drug delivery due to being highly cost-effective and offering simple manufacturing processes.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

First patients given lab-grown blood cell transfusion

European Pharmaceutical Review

Lab-grown blood cells have been transfused into a second patient in the world’s first-of-a-kind clinical trial , opening up future treatments for blood disorders such as sickle cell if found safe and effective. They anticipate patients who need regular blood transfusions could require fewer transfusions over time.

Patients 119
article thumbnail

Developing point-of-care CAR T manufacturing

European Pharmaceutical Review

2,3 Clinical implementation of CAR T-cell technology requires a reproducible T-cell manufacturing platform, which necessitates effective gene-transfer tools and T-cell culture conditions. As a result, many patients waiting for the CAR T cells to be infused will need additional therapy (bridging therapy) against the malignance.

article thumbnail

The FDA and Aduhelm: WTF?

World of DTC Marketing

SKIMMERS SUMMARY: Jefferies analysts found doctors have shown strong interest in prescribing Aduhelm for about 35% of early-stage Alzheimer’s patients with mild cognitive impairment after surveying 50 U.S. neurologists or psychiatrists currently treating about 12,000 Alzheimer’s patients. government.

FDA 218
article thumbnail

Less Is More—A Sharper Focus on Patient Needs Improves Adherence

PM360

“Drugs don’t work in patients who don’t take them,” C. 1 In addition, of patients who began therapy, more than 70% were no longer on their prescribed medication after 12 months. 1 In addition, of patients who began therapy, more than 70% were no longer on their prescribed medication after 12 months. Everett Koop, MD, U.S.

article thumbnail

Patient centricity for tailor-made healthcare

European Pharmaceutical Review

What is patient centricity and why is it an important consideration in drug development? Patient centricity is the process of obtaining the patients’ voice and making them active participants; identifying their needs and utilising them to improve decision-making in the healthcare arena.